European CHMP recommends approval of salmeterol / fluticasone (BroPair Spiromax and Seffalair Spiromax) for treatment of asthma

Both products, which are identical, are intended to be licensed for the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonists.

Source:

European Medicines Agency